Risanamento Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Risanamento.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Real Estate earnings growth | 62.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Risanamento's (BIT:RN) Strong Earnings Are Of Good Quality
Apr 20
Take Care Before Diving Into The Deep End On Risanamento SpA (BIT:RN)
Feb 20Market Cool On Risanamento SpA's (BIT:RN) Revenues Pushing Shares 25% Lower
Oct 04Is Risanamento (BIT:RN) Using Debt In A Risky Way?
Feb 01Is Risanamento (BIT:RN) Using Too Much Debt?
Oct 20Can You Imagine How Risanamento's (BIT:RN) Shareholders Feel About The 94% Share Price Increase?
Feb 27Is Risanamento (BIT:RN) Using Debt Sensibly?
Jan 05
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Risanamento has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 596 | 11 | 40 | 40 | N/A |
| 9/30/2023 | 587 | -16 | 22 | 23 | N/A |
| 6/30/2023 | 587 | -21 | 92 | 93 | N/A |
| 3/31/2023 | 0 | -55 | -57 | -57 | N/A |
| 12/31/2022 | 2 | -54 | -44 | -44 | N/A |
| 9/30/2022 | 1 | -29 | -36 | -36 | N/A |
| 6/30/2022 | 2 | -27 | -38 | -37 | N/A |
| 3/31/2022 | 2 | -25 | -20 | -20 | N/A |
| 12/31/2021 | 2 | -25 | -37 | -37 | N/A |
| 9/30/2021 | 2 | -23 | -32 | -32 | N/A |
| 6/30/2021 | 1 | -23 | -30 | -30 | N/A |
| 3/31/2021 | 1 | -26 | -31 | -30 | N/A |
| 12/31/2020 | 2 | -26 | -30 | -30 | N/A |
| 9/30/2020 | 1 | -27 | -38 | -38 | N/A |
| 6/30/2020 | 13 | -28 | -29 | -29 | N/A |
| 3/31/2020 | 14 | -24 | -32 | -31 | N/A |
| 12/31/2019 | 14 | -24 | -27 | -27 | N/A |
| 9/30/2019 | 14 | -24 | -16 | -15 | N/A |
| 6/30/2019 | 3 | -24 | -30 | -30 | N/A |
| 3/31/2019 | 2 | -26 | -29 | -29 | N/A |
| 12/31/2018 | 2 | -28 | -29 | -29 | N/A |
| 9/30/2018 | 3 | -35 | -27 | -27 | N/A |
| 6/30/2018 | 3 | -36 | -15 | -15 | N/A |
| 3/31/2018 | 3 | -35 | -19 | -19 | N/A |
| 12/31/2017 | 4 | -35 | -26 | -26 | N/A |
| 9/30/2017 | 4 | -68 | N/A | -33 | N/A |
| 6/30/2017 | 6 | -63 | N/A | -35 | N/A |
| 3/31/2017 | 4 | -64 | N/A | -32 | N/A |
| 12/31/2016 | 6 | -64 | N/A | -29 | N/A |
| 9/30/2016 | 5 | -34 | N/A | -26 | N/A |
| 6/30/2016 | 3 | -38 | N/A | -32 | N/A |
| 3/31/2016 | 6 | -39 | N/A | -143 | N/A |
| 12/31/2015 | 4 | -40 | N/A | -147 | N/A |
| 9/30/2015 | 7 | -42 | N/A | -153 | N/A |
| 6/30/2015 | 11 | -50 | N/A | -191 | N/A |
| 3/31/2015 | 13 | -61 | N/A | -101 | N/A |
| 12/31/2014 | 76 | -71 | N/A | -104 | N/A |
| 9/30/2014 | 78 | -107 | N/A | -105 | N/A |
| 6/30/2014 | 81 | -110 | N/A | -71 | N/A |
| 3/31/2014 | 66 | -108 | N/A | -56 | N/A |
| 12/31/2013 | 22 | -90 | N/A | -65 | N/A |
| 9/30/2013 | 37 | -92 | N/A | -86 | N/A |
| 6/30/2013 | 49 | -92 | N/A | -88 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RN's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if RN's earnings are forecast to grow faster than the Italian market
High Growth Earnings: Insufficient data to determine if RN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if RN's revenue is forecast to grow faster than the Italian market.
High Growth Revenue: Insufficient data to determine if RN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RN's Return on Equity is forecast to be high in 3 years time